Related Experiment Videos
Hemolytic anemia provoked by recombinant alpha-interferon
1First Department of Internal Medicine, Mie University School of Medicine, Japan.
Journal of Gastroenterology
|December 1, 1995
Summary
Recombinant alpha-interferon therapy for hepatitis C can trigger severe hemolytic anemia. This condition improved after discontinuing interferon and using methyl-prednisolone treatment.
Area of Science:
- Hepatology
- Immunology
- Hematology
Background:
- Chronic hepatitis C is a significant global health concern.
- Recombinant alpha-interferon has been a treatment option for hepatitis C.
- Drug-induced hemolytic anemia is a known but complex adverse effect.
Observation:
- A 30-year-old female patient with chronic hepatitis C received recombinant alpha-interferon (10 million units/day for 4 weeks).
- The patient developed serious hemolytic anemia during interferon therapy.
- Coombs' tests were negative before and after interferon treatment.
Findings:
- The patient's hemolytic anemia resolved after discontinuing recombinant alpha-interferon.
- Methyl-prednisolone administration aided in the recovery from anemia.
- The clinical presentation strongly suggested interferon-induced hemolytic anemia, despite negative Coombs' tests.
Implications:
- This case highlights a potential severe adverse reaction to recombinant alpha-interferon therapy.
- It underscores the importance of monitoring for hematological complications during interferon treatment.
- Negative Coombs' tests do not rule out drug-induced hemolytic anemia.